Scientific Reports Retracted Prostate Cancer Study
The journal withdrew the paper due to duplicated data and unresolved figure irregularities.
Updated on Sept. 23, 2026 in Cancer
Editors at Scientific Reports have officially retracted a 2026 prostate cancer study after identifying significant irregularities. The findings related to PTEN gene function and cancer treatment responses are no longer considered reliable.
Why it matters
The retraction highlights the importance of rigorous peer review and visual data verification in oncology research. It ensures that clinicians and researchers rely only on validated evidence when evaluating potential prostate cancer treatment pathways.
The journal Scientific Reports retracted a 2026 study investigating PTEN and prostate cancer radio-curability after discovering image duplications. Investigators found 6 figures with irregularities, including a PTEN blot that matched a previous publication's CtIP expression blot.
The players
Scientific Reports
An open-access, peer-reviewed scientific journal that publishes primary research across all areas of the natural and clinical sciences.
The details
The retracted study aimed to link PTEN-assisted cell cycle checkpoints to improved sensitivity for PARP inhibitor treatments. During an audit, editors discovered that key western blot images—which measure specific protein expressions—had been duplicated from unrelated prior research. Because the authors could not account for these inconsistencies, the editors concluded that the study’s central scientific conclusions lacked sufficient evidence.
Timeline
September 23, 2026: The formal retraction notice was published by the journal.
Health Landscape
This retraction serves as a correction within the broader landscape of prostate cancer research, where gene-targeted therapies are constantly being evaluated. It demonstrates the continued evolution of Scientific Reports editorial oversight processes in identifying and removing unreliable data.
Patients and caregivers should be aware that this specific research on PTEN-targeted prostate cancer treatment is no longer considered medically accurate. Always discuss the validity of treatment claims or new therapeutic approaches with your oncologist before making any care decisions.
The takeaway
When scientific journals identify image duplication, they take corrective action to protect the integrity of medical literature. Readers should prioritize consulting clinical specialists who base care on peer-reviewed, verified studies rather than individual, uncorroborated research papers.
Further reading
For more information on how new research is validated, explore our Cancer section.
More information
View the official scientific article retraction notice for further details.
